Our medical and scientific team continues research to improve therapies and offer additional treatment options. Contact a BioXcellerator Patient Advocate to see if new treatments are available for your condition.

Schedule Your Free Consultation

Free Consultation

Stem Cell History: From Scientific Possibility to Regenerative Medicine

The discoveries that transformed a biological idea into a majorfield of research – and opened the door to new treatment methods.

Older than Penicillin

That’s right, the idea of a “stem cell” is literally older than penicillin. In the 1860s, 60 years before Alexander Fleming observed penicillin’s antibacterial effect in 1928, the term “stem cell” first appeared in scientific discourse. That does not mean stem-cell therapy predates antibiotics. It means the scientific concept has a much longer history than many people assume.

The Birth of Stem-Cell Science: the term stem cell first appears in scientific discourse in the 1860s

Stem cells did not arrive in medicine as a single discovery. Its history is a chain of advances:

  • First a theory that certain cells could generate other cells
  • Then experimental proof
  • Followed by the ability to isolate, grow, characterize these cells
  • Finally, carefully defined settings for use in patients

The earliest chapters began more than a century ago. In the late 1800s, scientists looked to unlock how organisms and blood develop. By the 1960s, Canadian researchers James Till, Ernest McCulloch and Louis Siminovitch provided experimental evidence that bone marrow contains cells capable of both self-renewal and producing mature blood cells. That work helped establish the modern definition of a stem cell.

Beginning in the 1980s, researchers learned to maintain stem-cell populations in the laboratory, clinicians expanded blood-forming stem-cell transplantation, and scientists investigated cells that would eventually be called mesenchymal stem cells – or, more cautiously today, mesenchymal stromal cells.

During this 160-year history, many advances were made in many different countries leading to the practice of Regenerative Medicine.

1981: Stem cells become a renewable laboratory tool

Like most medicine, it started with experiments in mice.

From Laboratory to Clinical Use timeline: 1960s-1970s, 1981, 1988, 1991, 1998

In 1981, two research groups independently established pluripotent stem-cell lines from mouse embryos. Martin Evans and Matthew Kaufman reported cultures derived from mouse blastocysts in Nature, while Gail Martin described related work in Proceedings of the National Academy of Sciences. “Pluripotent” means that a cell can give rise to many of the specialized cell types found in the body. (stay tuned that term becomes important!)

Scientists could now keep these cells growing in culture and study how they developed. Mouse embryonic stem cells became an important tool for exploring genes, development and disease, including through genetically modified mouse models.

This milestone did not mean that treatments were immediately available. It gave science something equally important: a reproducible platform for asking better questions.

1988: Umbilical-cord blood enters clinical transplantation

Another turning point came from blood-forming stem cells. In 1988, a child with the condition Fanconi anemia received the first successful transplant of blood collected from an umbilical cord. The procedure showed that cord blood could restore healthy blood production and serve as an alternative source of blood-forming stem cells.

Cord-blood transplantation is distinct from mesenchymal stem cell therapies. It demonstrated that tissue normally discarded after birth could contain clinically useful cells. Cord-blood banks subsequently expanded transplant options for patients without a suitable bone-marrow donor.

It also helped correct a misconception that still follows the field. Not all stem cells come from embryos. It is important to note that early human embryonic stem-cell research relied on embryos donated for research after IVF treatment, including surplus embryos that were no longer needed for reproductive purposes. These were medical waste. These were the very ones scientists used to extract stem cells from. The use of human embryos in research has remained an important ethical issue, with requirements for informed consent and oversight varying by jurisdiction.

Stem cells can be obtained from adult bone marrow, circulating blood, fat, dental tissue, placental tissue and the umbilical cord, among other sources. The source matters because different cells have different biological properties, risks and intended uses.

1991: Umbilical Cord Mesenchymal Stem Cells receive a name

The roots of mesenchymal stem-cell research reach back to the work of Alexander Friedenstein and colleagues in the 1960s and 1970s. They identified colony-forming cells from bone marrow that could contribute to tissues such as bone and cartilage. Yet the field lacked a simple organizing term.

In 1991, Arnold Caplan popularized the name “mesenchymal stem cells,” or MSCs. He proposed that these cells could be isolated, expanded and directed toward skeletal tissues, helping frame a new vision of cell-assisted repair. The concept energized research into bone, cartilage, tendon, muscle and other tissues.

At our clinic, we use mesenchymal stromal cells derived from Wharton’s jelly of donated umbilical cord tissue. The tissue is processed under controlled laboratory conditions, and the resulting cell preparations undergo defined quality-control testing before clinical use.

That name has become influential and debated. MSC preparations are heterogeneous, and not every cultured cell meets the strict definition of a stem cell. Many scientists therefore prefer “mesenchymal stromal cells” unless stemness has been demonstrated. The abbreviation MSC remains widely used for both terms, making clear characterization essential.

1998: Human embryonic stem-cell lines expand the horizon

James Thomson and colleagues reported human embryonic stem-cell lines that could remain undifferentiated in culture while retaining the capacity to form derivatives of the body’s three primary germ layers. The work created an unprecedented system for studying early human development, modeling disease, and exploring potential replacement tissues.

It also intensified ethical and political debates because the cells were derived from human 5-7 day embryos called blastocysts. That debate came to define public perceptions of “stem cells,” even though it applied to one category – not to adult stem cells or MSCs derived from donated post-birth tissues. Clear distinctions among cell types became essential.

2006–2007: Adult cells are reprogrammed

Breakthroughs and New Possibilities: 2006 ISCT criteria and 2006-2007 iPSC reprogramming

A major scientific surprise arrived in 2006, when Japan’s Shinya Yamanaka and Kazutoshi Takahashi showed a small set of defined factors could reprogram mature mouse cells into an embryonic-like pluripotent state. In 2007, teams led by Yamanaka and Thomson extended the approach to human cells. These became known as induced pluripotent stem cells, or iPSCs.

iPSCs changed the field. Researchers could create patient-specific lines without deriving them from an embryo, then investigate disease mechanisms, test drugs and develop tissue models. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine for this reprogramming discovery.

2006: The MSC field adopts common criteria

As MSC studies multiplied, comparing results became difficult. Cell populations could differ by donor, tissue source, isolation method, culture conditions and passage number. In 2006, the International Society for Cellular Therapy (ISCT) proposed minimum criteria for cultured human MSCs: they should adhere to plastic under standard culture conditions; show a defined pattern of surface markers; and demonstrate the capacity to differentiate into bone, fat and cartilage lineages in laboratory testing.

While these criteria did not prove that every MSC product would be safe or effective for every condition (thus the clinic and the system you choose matter!), they created a shared starting point. The distinction remains critical: identifying a cell population is not the same as demonstrating a clinical benefit. Clinical questions still require well-designed studies, transparent manufacturing standards and condition-specific evidence. This is why evidence-backed, physician-led, science-based is critical to your research.

The 2010s: From replacement cells to biological signaling

When Arnold Caplan introduced the term “mesenchymal stem cells” (MSCs) in 1991, the concept emphasized the cells’ ability to proliferate and differentiate into mesenchymal lineages in vitro, which caused early descriptions to suggest that MSCs traveled to damaged tissue, transformed into replacement cells and rebuilt it directly. Over time, however, research increasingly highlighted that their effects in living tissues may not primarily result from direct differentiation into replacement cells.

By the 2000s, Caplan and others proposed that MSCs act as “trophic mediators,” releasing cytokines, growth factors and other bioactive molecules that can influence surrounding cells and modulate tissue responses. This concept helped shift the field from viewing MSCs primarily as replacement cells toward understanding their role as biological signaling cells. In 2010, Caplan proposed the term “medicinal signaling cells” to reflect this emerging understanding of MSC function in vivo. While the term MSC remains widely used, the concept emphasized that their therapeutic effects may be mediated largely through secreted factors and interactions with the local environment rather than through direct formation of new tissue.

This shift expanded investigation into inflammatory, immune-mediated and degenerative conditions, while also raising the bar for evidence. Results can vary with cell source, dose, delivery route, manufacturing process and patient population. “MSC therapy” is therefore not one uniform intervention. The details of the cells and the protocol matter.

The importance of Wharton’s jelly

One increasingly studied MSC source is Wharton’s jelly, the connective tissue that cushions and protects the blood vessels inside the umbilical cord. These cells are obtained from donated, full-term birth tissue after delivery. They are not embryonic stem cells, and their collection does not require an embryo or fetal tissue.

Toward Regenerative Medicine: 2010s and 2023 milestones

Wharton’s jelly-derived MSCs attract research interest because the tissue is readily available after birth and the cells can be isolated and expanded under controlled conditions. Studies have examined their growth, surface markers, differentiation capacity and signaling properties. However, source alone does not establish quality. Donor screening, tissue handling, culture conditions, testing, release criteria, sterility, potency assessment and clinical oversight all influence the final cell preparation.

Where the science stands now

Stem-cell science now spans established medicine, experimental therapy and foundational research. Hematopoietic stem-cell transplantation is an established treatment for selected blood and immune disorders. Pluripotent stem cells and iPSCs are central tools in disease modeling, drug testing and emerging replacement-cell programs. In 2023, the U.S. Food and Drug Administration approved the first CRISPR-based therapy, which edits a patient’s own blood-forming stem cells for sickle cell disease – a striking example of stem-cell biology converging with gene editing.

MSCs occupy a different position. They have been investigated in a large and growing range of preclinical studies and clinical trials, but evidence, authorization and standard of care vary by product, condition and country. Promising findings should not be translated into guarantees. A responsible clinic should identify the cell source, explain how the cells are manufactured and tested, discuss the evidence for the specific condition, outline known and potential risks, and set realistic expectations.

The history of stem cells is not a straight line from discovery to cure. The story is still evolving – from better definitions, to better tools, to increasingly precise questions. The field’s most important lesson may be this: the phrase “stem cells” is only the beginning of the conversation. Understanding which cells, from what source, prepared in what way, and supported by what evidence is what turns scientific possibility into informed decision-making. This can make all the difference.

Sources

  1. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154–156. doi:10.1038/292154a0.
  2. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA. 1981;78:7634–7638. doi:10.1073/pnas.78.12.7634.
  3. Gluckman E, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–1178. doi:10.1056/NEJM198910263211707.
  4. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–650. doi:10.1002/jor.1100090504.
  5. Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–1147. doi:10.1126/science.282.5391.1145.
  6. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676. doi:10.1016/j.cell.2006.07.024.
  7. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8:315–317. doi:10.1080/14653240600855905.
  8. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98:1076–1084. doi:10.1002/jcb.20886.
  9. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872. doi:10.1016/j.cell.2007.11.019.
  10. U.S. Food and Drug Administration. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. December 8, 2023.
  11. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10:226–236.

Medical note: This article is for education and does not provide medical advice. The availability, regulatory status and evidence supporting cell-based interventions vary by product, condition and jurisdiction.

BioXcellerator, 4900 N. Scottsdale Rd, Suite 3700, Scottsdale, AZ 85251
BioXcellerator, Torre Medica 2, Office 944, Medellin, Colombia